Media coverage about Radius Health (NASDAQ:RDUS) has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Radius Health earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.3337597463608 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern’s rankings:

A number of brokerages have weighed in on RDUS. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the company a “buy” rating in a research note on Sunday, July 23rd. BidaskClub lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $38.00 target price (up from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. Radius Health presently has a consensus rating of “Hold” and a consensus price target of $52.17.

Radius Health (RDUS) traded down 2.056% during midday trading on Wednesday, hitting $36.445. The stock had a trading volume of 332,518 shares. Radius Health has a 52-week low of $31.58 and a 52-week high of $55.97. The firm’s market capitalization is $1.59 billion. The firm has a 50-day moving average of $36.69 and a 200 day moving average of $38.73.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The company had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the previous year, the business posted ($1.01) earnings per share. On average, equities analysts forecast that Radius Health will post ($5.55) EPS for the current year.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 60,000 shares of Radius Health stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average price of $35.98 per share, with a total value of $2,158,800.00. Following the completion of the acquisition, the insider now directly owns 5,248,799 shares in the company, valued at approximately $188,851,788.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jesper Hoiland bought 6,100 shares of Radius Health stock in a transaction that occurred on Friday, September 15th. The shares were acquired at an average cost of $32.72 per share, with a total value of $199,592.00. Following the acquisition, the insider now owns 6,100 shares of the company’s stock, valued at $199,592. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 469,100 shares of company stock valued at $16,328,382. 15.00% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/11/radius-health-rdus-receives-news-impact-score-of-0-20.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.